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Abstract
The multi-functional apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) DNA repair and
redox signaling protein has been shown to have a role in cancer growth and survival, however,
little has been investigated concerning its role in inflammation. In this study, an APE1 redox-
specific inhibitor (E3330) was used in lypopolysaccharide (LPS)-stimulated macrophages
(RAW264.7). E3330 clearly suppressed secretion of inflammatory cytokines including tumor
necrosis factor-α (TNF-α), interleukin (IL-6) and IL-12 and inflammatory mediators nitric oxide
(NO) as well as prostaglandin E2 (PGE2) from the LPS-stimulated RAW264.7 cells. These data
were supported by the down-regulation of the LPS-dependent expression of inducible nitric oxide
synthase (iNOS) and cyclooxygenase-2 (COX-2) genes in the RAW264.7 cells. The effects of
E3330 were mediated by the inhibition of transcription factors nuclear factor-κB (NF-κB) and
activator protein 1 (AP-1) in the LPS-stimulated macrophages, both known targets of APE1. In
conclusion, pharmacological inhibition of APE1 by E3330 suppresses inflammatory response in
activated macrophages and can be considered as a novel therapeutic strategy for the inhibition of
tumor-associated macrophages.
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Apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1 or APE1) is a multifunctional
protein which functions as the DNA base excision repair protein and as a redox signaling
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factor keeping transcription factors in an active reduced state (1, 2). APE1 stimulates the
DNA binding activity of a number of transcription factors involved in cancer and
inflammation (e.g. activator protein 1 [AP-1], nuclear factor-κB [NF-κB], hypoxia-inducible
transcription factor 1α [HIF-1α], cAMP response-element binding [CREB], p53 and others);
thus, APE1 has been suggested as a therapeutic and chemopreventive target (1–8). Indeed,
E3330, a small-molecule inhibitor of the APE1 redox domain, suppressed proliferation and
migration of pancreatic cancer cells and inhibited growth of pancreatic cancer-associated
endothelial cells, respectively (9–11). APE1 was significantly increased in the colon
epithelium in patients with ulcerative colitis, a precursor of colon cancer (12). Moreover,
APE1 modulated inflammatory responses through Toll-like receptor 2 (TLR2) by the
activation of NF-κB and HIF-1α resulting in the expression of inflammatory cytokines and
chemokines tumor necrosis factor-α (TNF-α) and chemokine (C-X-C motif) ligand 8
(CXCL8) in primary keratinocytes (13).
The tumor microenvironment contains stromal cells such as fibroblasts, endothelial cells,
and macrophages. In spite of the importance of macrophages in the host-defense mechanism
and inflammation (14, 15), the overproduction of inflammatory mediators by macrophages
has also been implicated in cancer (16), whereas anti-inflammatory drugs reduce the risk of
cancer (17). Further, a high density of tumor-associated macrophages correlates with poor
prognosis in a majority of published studies, including those on breast, prostate, bladder,
kidney, endometrial and esophageal carcinomas (18, 19). Thus, the inflammatory stimuli
from macrophages promote cancer growth (20–22), whereas the reduction of macrophages
results in the decrease of tumor growth (22). Macrophage activations result in the secretion
of a number of different inflammatory mediators, including TNF-α, interleukin-6 (IL-6),
reactive oxygen species (ROS), prostaglandin E2 (PGE2) and nitric oxide (NO) (23–29).
Lipopolysaccharide (LPS), a constituent of the gram-negative bacterial cell wall, interacts
with TLR4, which is expressed on macrophages (30, 31). The interaction between LPS and
the TLR4 receptor complex activates intracellular signaling through myeloid differentiation
primary response gene 88 (MyD88) and TIR-domain-containing adapter-inducing
interferon-β (TRIF) pathways leading to the activation of transcription factors NF-κB and
AP-1 and the expression of TNF-α and IL-6 (32, 33). In addition, LPS induces expression of
IL-12 in macrophages through NF-κB (27, 34), and AP-1 (35). Moreover, LPS-dependent
expression of cyclooxygenase-2 (COX-2), which controls production of PGE2, and
inducible nitric oxide synthase (iNOS), which controls production of NO, is also regulated
through NF-κB and AP-1 (36).
In the present study, the anti-inflammatory activity of E3330, a small-molecule inhibitor of
APE1 redox signaling function, was investigated in LPS-challenged RAW264.7
macrophages.
Materials and Methods
Cell culture
RAW264.7 cells, a murine macrophage cell line (American Type Culture Collection,
Manassas, VA, USA), were cultured in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin. The
RAW264.7 cells were plated at a density of 2–3×106 and cultivated at 37°C in a humidified
atmosphere containing 5% CO2. For all the experiments, the cells were grown to 80–90%
confluence. The RAW264.7 cells were stimulated with 1 μg/ml LPS (Sigma, St. Louis, MO,
USA). The cells were incubated with or without E3330 in the serum free medium for 1 hour
before exposure to LPS. E3330 was synthesized as previously published (4, 37, 38), and
used as described in the individual experiments.
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Expression of pro-inflammatory mediators in RAW264.7 cells
The RAW264.7 cells were preincubated with 0–25 μg/ml E3330 for 24 hours followed by
an additional 24 hours’ incubation with LPS (1 μg/ml). The levels of TNF-α, IL-6, IL-12p40
(Biolegend, San Diego, CA, USA) and PGE2 (R&D Systems, Minneapolis, MN, USA) were
determined by ELISA; the release of NO was determined by Griess reagent (Sigma) as
previously described (39).
Preparation of whole-cell and nuclear extracts
After E3330 and LPS treatments (the whole-cell and nuclear extracts were prepared as
described previously (39). The protein concentration in the whole-cell and nuclear extracts
was determined according to the manufacturer’s protocol (Bio-Rad Laboratories, Hercules,
CA, USA).
Western blot analysis
Western blot analysis was performed as previously described (39), on RAW264.7 cells
pretreated with E3330 (0–25 μg/ml) for 24 hours followed by LPS (1 μg/ml) for 24 hours.
Briefly, the total cell lysates were separated by SDS–PAGE and were transferred to a
polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% bovine
serum albumin in TBS-Tween 20 solution and was further incubated with the corresponding
antibody: COX-2 (BD Biosciences, San Jose, CA, USA), iNOS and β-actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Reactive bands were visualized with horseradish
peroxidase (HRP)-coupled secondary antibody via an enhanced chemiluminescence (ECL)
detection system (Amersham Pharmacia Biotech, Little Chalfont, UK) according to the
manufacturer’s procedures.
Electrophoretic mobility shift assay (EMSA)
The nuclear extracts from RAW264.7 cells pretreated with E3330 (0–25 μg/ml) for 24 hours
followed by LPS (1 μg/ml) for 30 minutes were used. Oligonucleotide probes containing
consensus sequences for AP-1-and NF-κB-binding sites were purchased from Promega
(Madison, WI, USA). EMSA for AP-1 and NF-κB was performed with a 32P-AP-1 or 32P-
NF-κB probe in gel shift binding buffer with 5 μg of nuclear protein as previously described
(39). The specificity was confirmed by competitive EMSA with cold AP-1 or NF-κB
oligonucleotide or unrelated DNA (URL).
Statistical analysis
Data are presented as mean±S.D and were analyzed by Student t-test. Results were
considered significant if p≤0.05.
Results
Effect of E3330 on LPS-dependent production of pro-inflammatory cytokines
As expected, LPS stimulation markedly induced the production of TNF-α from the
RAW264.7 cells, whereas pretreatment with E3330 at doses 12.5 and 25 μg/ml significantly
suppressed TNF-α production from these macrophage cells (Figure 1A). In addition, E3330
(6.25–25 μg/ml) also significantly suppressed IL-6 production from LPS-stimulated
RAW264.7 cells (Figure 1B). Moreover, LPS-dependent production of IL-12 in
macrophages was also markedly suppressed by E3330 in a dose-dependent manner (Figure
1C).
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Effect of E3330 on LPS-dependent secretion of PGE2 and NO and on the regulation of
expression of COX-2 and iNOS
E3330 treatment markedly decreased the secretion of the LPS-induced inflammatory
mediators PGE2 (Figure 2A) and NO (Figure 2B) in a dose-dependent manner. Because the
production of PGE2 and NO is controlled by COX-2 and iNOS, respectively, the expression
of COX-2 and iNOS was evaluated by Western blot. As shown in Figure 2C, LPS induced
the expression of COX-2 in the RAW264.7 cells, whereas E3330 pretreatment suppressed
this LPS-dependent expression. In addition, the LPS-induced expression of iNOS was also
markedly reduced by the E3330 in the macrophages (Figure 2D).
Effect of E3330 on LPS-inducible NF-κB and AP-1 activation
NF-κB and AP-1 DNA-binding activity was evaluated in nuclear extracts by gel shift
analysis. As shown in Figure 3A, LPS markedly induced the binding activity of nuclear
extracts to the NF-κB DNA consensus sequence, whereas pretreatment of the macrophages
for 24 hours with E3330 (12.5 and 25 μg/ml) suppressed the LPS-dependent increase of NF-
κB binding. As expected, the binding activity of AP-1 in nuclear extracts was also induced
by the LPS treatment, and E3330 pretreatment suppressed this LPS-dependent binding
activity of AP-1 in the RAW264.7 cells (Figure 3B).
Discussion
The inhibition of APE1 redox signaling function by the APE1-specific small molecule
E3330 suppressed the LPS-dependent production of pro-inflammatory cytokines, TNF-α,
IL-6, and IL-12, and inflammatory mediators, NO and PGE2, in the murine macrophages
RAW264.7 cells. The inhibition of secretion of NO and PGE2 by E3330 was mediated
through the down-regulation of expression of iNOS and COX-2, respectively. In addition,
E3330 inhibited the LPS-dependent induction of NF-κB and AP-1. Mechanistically, E3330
inhibits or blocks the redox function of APE1 resulting in the cysteine residues located in the
DNA binding domain of p50 (NF-κB) and Fos and Jun (AP-1) not being converted from an
oxidized to a reduced status. This results in the inability of NF-κB and AP-1 to bind to their
respective DNA target sequences (Figure 4) (40, 41).
The present study was in congruence with original reports demonstrating the suppression of
LPS-dependent production of TNF-α by E3330 through the inhibition of NF-κB in
macrophages and monocytes (42, 43). The inhibition of TNF-α by E3330 has also been
associated with the protection against endotoxin-mediated hepatitis and alcoholic liver
injury (44, 45). However, the data presented here demonstrates, for the first time, that the
inhibition of NF-κB and AP-1 by E3330 can directly suppress production of IL-6, IL-12,
PGE2 and NO and down-regulate expression of COX-2 and iNOS in activated macrophages.
APE1 has been the focus of a number of studies, from use as a diagnostic aid in cancer
screening (46) to a suitable target for the prevention or treatment of cancer (1). However,
more intensive studies have focused on both repair and redox functions of APE1 as a novel
therapeutic target in cancer (3–5). Although recent studies have demonstrated a direct effect
of E3330 on a variety of cancer cells (1, 9, 37, 38–34, 47–51), the inhibition of the
inflammatory response by E3330 in activated macrophages is of particular interest.
The inhibition of NF-κB and AP-1 signaling in activated macrophages by E3330 could have
a potential therapeutic effect as NF-κB and AP-1 are necessary for the inflammatory
response leading to the production of TNF-α, IL-6, IL-12, NO and PGE2 and other
inflammatory mediators in these cells (23–29). As mentioned above, a link between
activated macrophages and cancer has been demonstrated (18, 20–22), and a recent study
further confirmed that an increased number of tumor-associated macrophages was strongly
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associated with shortened survival of cancer patients (19). Although the depletion of
macrophages with clodronate inhibited tumor recovery after irradiation (52), this strategy
would also deplete other non-tumor-associated macrophages and would therefore interrupt
the homeostatic function of macrophages in the gut, liver, lung and spleen in humans (53).
Therefore, direct targeting of tumor-associated macrophages is a more plausible strategy.
Blocking TNF-α with TNF-α receptor or inhibiting macrophage recruitment by macrophage
antibodies inhibited tumor regrowth after tumor irradiation, respectively (52, 54). Another
possible strategy would be the inhibition of secretion of pro-inflammatory cytokines and
mediators from macrophages by E3330 as presented in the current study.
In summary, E3330 exerts an anti-inflammatory effect by blocking the ability of APE1 to
convert NF-κB and AP-1 from an oxidized to a reduced state. These two transcription
factors have been implicated in signaling in LPS-activated macrophages, Thus E3330
treatment results in the suppression of the production of pro-inflammatory cytokines and
mediators. The inflammatory response in LPS-stimulated macrophages controlled by APE1
and has a potential clinical applicability to affect the tumor microenvironment as having
direct effects on tumor cells. The demonstration of an anti-inflammatory activity of E3330
provides further proof-of-concept data promoting the development of E3330 as an anti-
inflammatory agent for the inhibition of the detrimental function of tumor-associated
macrophages in cancer treatment. Furthermore, it continues to illustrate the important
function of APE1 redox signaling in the control of the tumor microenvironment.
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Figure 1.
Effect of E3330 on LPS-induced production of pro-inflammatory cytokines in RAW264.7
cells. (A) TNF-α, (B) IL-6 (C) IL-12 production in cell culture media from RAW264.7 cells
pretreated with E3330 for 24 hours followed by LPS for an additional 24 hours. Each value
is the mean±S.D. of two independent experiments, repeated minimally twice. *p<0.05
control vs. LPS alone, *p<0.05 LPS vs. LPS plus E3330.
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Figure 2.
Effect of E3330 on LPS-induced PGE2, NO, COX-2 and iNOS expression in RAW264.7
cells. RAW264.7 cells were pretreated with E3330 for 24 hours followed by LPS for 24
hours. (A) PGE2 and (B) NO in cell culture media. Each value is the mean±S.D. of two
independent experiments, repeated minimally twice. p<0.05 control vs. LPS alone, *p<0.05
LPS vs. LPS plus E3330. (C) COX-2 and (D) iNOS determined in lysates by Western blot
analysis. The equal protein loading was verified with anti-β-actin antibody. The results are
representative of three separate experiments.
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Figure 3.
Effect of E3330 on NF-κB and AP-1 DNA-binding. RAW264.7 cells were pretreated with
E3330 for 24 hours followed by the LPS (1 μg/ml) treatment for 30 min. Nuclear extracts
were subjected to gel shift analysis with (A) [32P]-labeled NF-κB probe or [32P]-labeled
AP-1 probe. The specificity was confirmed by the competitive gel shift in LPS-stimulated
cells with cold NF-κB or AP-1 or unrelated DNA (URL). The data are representative of
three separate experiments.
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Figure 4.
Schematic illustration of the relationship of affected molecules and pathways following
inhibition of Ref-1 (APE1) redox function with E3330. Blocking Ref-1 with the small
molecule Ref-1 redox inhibitor E3330 inhibits NF-κB function and most likely other
transcription factors that are downstream of Ref-1 such as AP-1 and CREB leading to a
decrease in synthesis of COX2, IL-12, IL-6, TNF-α and iNOS. Decreased levels of iNOS
result in decreased NO produced. Decreased production of COX2 leads to fewer AA being
converted by COX2 and eventually to PGE2 which could result in a signaling cascade
decrease that further suppresses iNOS production via CREB suppression. NFAT, Nuclear
factor of activated T-cells; PPAR, peroxisome proliferator-activated receptor; CREB, cAMP
response element-binding; PR, prostagladin receptors; C/EBP, CCAAT-enhancer binding
proteins. The red lettering signifies molecules measured in the present study.
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